YMB YM Bio.'b'ser1

    YM BioSciences reports anti-EGFr drug nimotuzumab approved in India for
treatment of head and neck cancer

    MISSISSAUGA, ON, July 20 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,
AIM:YMBA), a company engaged in the acquisition, development and
commercialization of oncology and acute care products, today reported that
India's Drug Controller General has granted marketing approval to nimotuzumab,
an anti-EGFr monoclonal antibody, for the treatment of head & neck cancer.
Biocon Biopharmaceuticals Ltd, a joint venture between Biocon (NSE:BIOCON) and
CIMAB SA (Havana, Cuba), has rights to the drug from CIMAB for the Indian
subcontinent. Nimotuzumab is also licensed to YM's majority owned subsidiary
CIMYM BioSciences Inc. by CIMAB for the major market countries including
Europe, North America, Japan and the Pacific Rim countries excluding China.
    "While our license for nimotuzumab does not extend to India, this
approval is an important validation of the safety and efficacy of the drug. In
addition, a significant amount of additional clinical data in head & neck
cancer will be now generated in India as nimotuzumab is commercialized," said
David Allan, Chairman and CEO of YM BioSciences. "YM has been advised that in
the trials undertaken by Biocon Biopharmaceuticals Ltd to gain approval for
nimotuzumab no cases were observed of the severe rash commonly produced by
similar agents with the same target, consistent with previous study results.
The absence of this debilitating side-effect should prove a key differentiator
for nimotuzumab in the marketplace."
    Nimotuzumab is currently in a Phase IIl trial in Europe in combination
with radiation for the treatment of pediatric pontine glioma. YM BioSciences
and CIMYM BioSciences Inc. are preparing to file for authorization to conduct
a trial in North America in pediatric pontine glioma. In addition, YM is
developing nimotuzumab for non-small cell lung cancer and pancreatic cancer
and proposes to pursue the clinical development of the drug in adult glioma,
esophageal cancer and colorectal cancer. YM's licensor, CIMAB SA and its
parent, the Center of Molecular Immunology, are conducting trials with
nimotuzumab in glioma, breast, esophageal, uterine cervix, prostate and head
and neck cancers.
    Data from trials with nimotuzumab were submitted to the ASCO 2006 Annual
Meeting in Atlanta, Georgia in June 2006, and included safety data from a
pharmacodynamic/pharmacokinetic study of nimotuzumab conducted by The Princess
Margaret Hospital. Full PD/PK results will be presented at the 18th
EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics", which
will be held in Prague, Czech Republic from November 7-10, 2006.

    About YM BioSciences
    YM BioSciences Inc. is a cancer product development company. Its lead
drug, tesmilifene, is a small molecule chemopotentiator currently undergoing a
700-patient pivotal Phase III trial in metastatic and recurrent breast cancer.
In addition to tesmilifene, YM BioSciences is developing nimotuzumab, an
anti-EGFr humanized monoclonal antibody, in a number of indications and
AeroLEF(TM), a unique inhalation delivered formulation of the established
drug, fentanyl, to treat acute pain including cancer pain. YM BioSciences is
also developing its anti-GnRH, anti-cancer vaccine, Norelin(TM), and owns a
portfolio of preclinical compounds.

    Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

For further information: Enquiries: Thomas Fechtner, The Trout Group LLC,
Tel. (212) 477-9007 x31, Fax (212) 460-9028, Email:
tfechtner@troutgroup.com; James Smith, the Equicom Group Inc., Tel. (416)
815-0700 x 229, Fax (416) 815-0080, Email: jsmith@equicomgroup.com
YMBA

 



END

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jun 2024 to Jul 2024

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jul 2023 to Jul 2024